$6.30
2.44%
Nasdaq, Sep 25, 04:00 pm EDT. Closed.
ISIN
KYG0367B1059
Symbol
NNNN

Anbio Biotechnology Stock price

$6.30
-1.53 19.54% 1M
-17.46 73.48% 6M
-23.77 79.05% YTD
-29.52 82.41% 1Y
+1.30 26.00% 3Y
+1.30 26.00% 5Y
+1.30 26.00% 10Y
+1.30 26.00% 20Y
Nasdaq, Closing price Fri, Sep 25 2026
+0.15 2.44%
ISIN
KYG0367B1059
Symbol
NNNN
Industry

Is Anbio Biotechnology a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$906.5m
Enterprise Value
$894.6m
Net debt
positive
Cash
$11.9m
Shares outstanding
143.9m
Valuation (TTM | estimate)
P/E
27.4
P/S
68.5 | -
EV/Sales
67.6 | -
EV/FCF
-
P/B
30.1
Financial Health
Equity Ratio
99.7%
Return on Equity
21.2%
ROCE
30.3%
ROIC
50.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$13.2m | -
EBITDA
-
EBIT
$9.1m
Net Income
$10.2m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
-5.7% | -
EBITDA
-
EBIT
63.3%
Net Income
70.9%
Free Cash Flow
-
Margin
Gross
89.0%
EBITDA
-
EBIT
69.0%
Net
77.1%
Free Cash Flow
-
More
EPS
$0.2
FCF per Share
-
Short interest
0.1%
Employees
27
Rev per Employee
$320.0k

Financial data from Anbio Biotechnology

Dec '25
+/-
%
13 13
6% 6%
100%
- Direct Costs 1.46 1.46
66% 66%
11%
12 12
20% 20%
89%
- Selling and Administrative Expenses 2.31 2.31
36% 36%
17%
- Research and Development Expense 0.33 0.33
43% 43%
2%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 9.14 9.14
63% 63%
69%
Net Profit 10 10
71% 71%
77%

In millions USD.

Don't miss a Thing! We will send you all news about Anbio Biotechnology directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Anbio Biotechnology is a medical device company. The company is headquartered in Frankfurt, Hessen and currently employs 27 full-time employees. The company went IPO on 2025-02-19. The firm is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).

Head office Germany
CEO Mr. Lau
Employees 27
Website anbiobiotechnology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today